Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saruparib (AZD5305) Bioavailability and ADME Study in Advanced Solid Malignancies
NCT06713369Phase 1Recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of saruparib in solid tumor, sponsored by AstraZeneca. Primary endpoints: Absolute bioavailability (F) of Saruparib at Day 4, Total radioactivity recovery in urine and faeces at Day 8 and 7 more. Started Apr 2025; status: recruiting.
02
Drugs
saruparib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06713369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06713369.